Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 3

KERYX BIOPHARMACEUTICALS INC Form 3 October 07, 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 3 Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB 3235-0104 Number: January 31, Expires: 2005 Estimated average burden hours per response... 0.5

6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting

Form filed by More than One

Person

Reporting Person

(Print or Type Responses)

1. Name and Address of Reporting Person <u>*</u> Regan Daniel Paul			2. Date of Event Requiring Statement (Month/Day/Year)	³ 3. Issuer Name and Ticker or Trading Symbol KERYX BIOPHARMACEUTICALS INC [KERX]				
(Last)	(First)	(Middle)	10/03/2013	4. Relationship of Reporting Person(s) to Issuer		5. If Amendment, Date Original Filed(Month/Day/Year)		
C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON				(Check al	l applicable)			
INC.,A 750 AVENUE) LEXING'.	ľON		X_ Director Officer	10% Owner Other			
	(Street)			(give title below)	(specify below)	6 Individual on Joint/Crown		

(Street)

(State)

NEW YORK, NYÂ 10022

(City)

Table I - Non-Derivative Securities Beneficially Owned

SEC 1473 (7-02)

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock (Restricted)	10,000 (1)	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

(Zip)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative	2. Date Exercisable and	3. Title and Amount of	4.	5.	6. Nature of Indirect
Security (Instr. 4)	Expiration Date (Month/Day/Year)	Securities Underlying Derivative Security	Conversion or Exercise	Ownership Form of	Beneficial Ownership
(1150.1)		Derivative Security	of Excicise	1 01111 01	Ownership

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 3

	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	(Instr. 5)
Stock Options (Right to Buy)	10/03/2014(2)	10/03/2023	Common Stock	50,000	\$ 10.21	D	Â

Reporting Owners

Reporting Owner Name / Address		Relationships				
· · · · · · · · · · · · · · · · · · ·	Director	10% Owner	Officer	Other		
Regan Daniel Paul C/O KERYX BIOPHARMACEUTICALS 750 LEXINGTON AVENUE NEW YORK, NY 10022	S, INC.	ÂX	Â	Â	Â	
Signatures						
/s/ James F. Oliviero, Attorney-in-Fact	10/07/2	013				
**Signature of Reporting Person	Date					

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The shares of restricted stock vest as follows: 1/3 of each on October 4, 2014, October 4, 2015, and October 4, 2016.

(2) The options vest as follows: 16,667 on October 3, 2014; 16,667 on October 3, 2015; and 16,666 on October 3, 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.